echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Eur Respir J: Interstitial lung disease increases susceptibility and severity of COVID-19

    Eur Respir J: Interstitial lung disease increases susceptibility and severity of COVID-19

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Data on the correlation between interstitial lung disease (ILD) and the natural course of 2019 new coronary pneumonia ( COVID-19 ) are very limited.


    The new crown pneumonia COVID-19

    Recently, an authoritative journal in the field of respiratory diseases published a research article in Eur Respir J.


    infection

    From January 1, 2020 to May 30, 2020, researchers formed a nationwide cohort of COVID-19 patients (n=8070) and a 1:15 ratio matched control based on age, gender, and area of ​​residence.


    The proportion of ILD patients in the COVID-19 patient cohort was significantly higher than that in the matched cohort (0.


    It can be seen that the risk and serious manifestations of COVID-19 infection in ILD patients are significantly higher than that of non-ILD patients .


    ILD patients have significantly higher risk and severe manifestations of COVID-19 than non-ILD patients

    Original source:

    Original source:

    Hyun Lee,et al.


    ersjournals.
    com/content/early/2021/04/19/13993003.
    04125-2020" target="_blank" rel="noopener">Interstitial lung disease increases susceptibility to and severity of COVID-19 in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.